Presentation of the platform
The Proteomic platform (proteomic platform) specializes in advanced protein analysis. It offers research teams essential equipment for:
- The production of recombinant proteins (FPLC (Akta Pure) systems, lyophilizer, sounder, etc.).
- The amplification of the poor folding of proteins (several BMG Labtech Omega).
- Multiplexed and highly sensitive immunoderation (Meso Quickplex SQ120-MSD, Simoa HD-X).
We also ensure the preparation and fractionation of samples for basic analyzes by Western Blot and Dot Blot, as well as protein extraction for analyzes in mass spectrometry.
Thanks to a framework contract and the collaboration between the SMBC platforms of the ESPCI and Ican omics for metabolomics and lipidomics, researchers will have access to advanced technologies, in particular:
- Maldi and LC-MS/MS for advanced proteomic analysis.
- Unicellular proteomics and MS imaging.
- Cellular metabolism analysis.
- Quantitative and ultra-sensitive analyzes on hundreds of lipid species in various organic matrices.
In the near future, we will provide devices allowing the structural analysis of proteins and their aggregate states via spectrometry techniques, light diffusion and calorimetry. In close collaboration with the Igenseq platform, we will also implement advanced immunodetection technologies, such as Alamar Biosciences and Olink. In the coming years, efforts will be made to establish collaborations allowing access to structural biology technologies requiring specific expertise, such as electron cryo-misscopy and crystallography.
This platform will make it possible to study proteins and their interactions, their various isoforms, their aggregate states as well as their post-transduction modifications (PTM). It will contribute in particular to research on illnesses linked to the poor folding of proteins, such as Alzheimer’s disease, Parkinson or Huntington, as well as to the study of other neurodegenerative diseases and brain pathologies, in particular brain tumors, vascular diseases and epilepsy.
Scientific director : Stéphane Haïk, MD, PHD, Dr1 Inserm
Operational director : Katarina Grznarova, PHD, research engineer
